Navigation Links
CoreSpine Technologies(TM) Receives Clearance to Market Surgical Disc Preparation Device
Date:5/4/2009

Company Achieves Major Milestone with Limited Start-up Funding

MINNEAPOLIS, May 4 /PRNewswire/ -- CoreSpine Technologies, a Minneapolis-based spinal device developer, announced today it has received 510(k) clearance to market from the U.S. Food and Drug Administration (FDA) for its XTEND-ST(TM) Nucleus Removal System.

"The clearance of the XTEND-ST device is truly a significant achievement for CoreSpine," said Christine Horton, Chief Executive Officer of CoreSpine Technologies. "The XTEND-ST is a safe and effective device for removing lumbar disc material and satisfies a large unmet need within the spine industry. Of equal significance is that CoreSpine was able to develop the product with minimal funding over the past three years. I credit the many dedicated and talented medical device professionals that work with CoreSpine and the company's ability to operate lean yet with a defined purpose."

"The need for CoreSpine's technology increases as additional spinal implants and new approaches are introduced to spine surgeons," said John Sherman, M.D., spine surgeon with Twin Cities Orthopedics in Minneapolis, Minnesota. Dr. Sherman continued, "I continue to be impressed with the company's history of developing new technology with limited funds."

About CoreSpine Technologies, LLC

CoreSpine Technologies, LLC is a privately held spinal device manufacturer headquartered in Minneapolis, Minnesota. The company's focus is on expanding its platform technology to produce advanced surgical devices for the complete or selective removal of material from the lumbar disc space. The first products will initially set the standard for preparing the spinal disc for minimally invasive fusion with applications in a variety of emerging spinal therapies. For additional information, please visit the company's website at www.corespinetech.com
'/>"/>

SOURCE CoreSpine Technologies, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Baxa Corporation Acquires Florida-Based ForHealth Technologies(TM)
2. Insurance Defense Law Firm Receives Recognition from Martindale-Hubbell
3. BMP Sunstone Receives Nasdaq Compliance Notice
4. BMP Sunstone Compliance Receives Nasdaq Notice
5. Stratfords Institutional Investment Consulting Service Receives HFMA Peer Review Designation
6. Excelsior Medical Corporation Receives FDA Approval to Market SwabCap(TM) Luer Access Valve Disinfection Cap
7. Solta Medical Receives Regulatory Approval to Market Thermage Systems in China
8. IMRIS receives CE Mark approval for interventional imaging system
9. Insulet Receives CE Mark for the OmniPod(R) Insulin Management System
10. Houston Northwest Medical Center Receives Prestigious Tenet Circle of Excellence Award
11. SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... chronic inflammation in benign prostate tissue was associated ... association was found even in those with low ... published in Cancer Epidemiology, Biomarkers & Prevention ... Cancer Research. , An analysis of prostate tissue ... arm of the Prostate Cancer Prevention Trial (PCPT) ...
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... 17, 2014U.S. military personnel who served in Iraq ... traumatic brain injury (TBI) were compared to military ... medical reasons. Differences in measures of overall disability, ... after injury are reported in an article in ... from Mary Ann Liebert, Inc., publishers. The article ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... by conservative political operative with ties to convicted lobbyist Jack ... Action Fund issued a new investigative report today called "Viewers ... the political ads running in eight states, including Virginia, to ... Americans for Prosperity Foundation, which has a record as a ...
... found some also suffer PTSD years after treatment , ... survivors aren,t following recommended guidelines on screenings for second ... suffer from post-traumatic stress disorder years after beating their ... guidelines can be costly because childhood cancer survivors are ...
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced ... Administration (FDA) that the Dermatologic and Ophthalmic Drugs Advisory Committee ... ophthalmic solution) on June 26, 2009. , , On ... with the FDA for Bepreve as an eye drop treatment ...
... Minnesota has become the first state in the nation ... providers to electronically submit insurance claims to health plans, ... referred to as the E3 Initiative, will also require ... eligibility for insurance coverage and benefits, as well as ...
... U.S.A. (June 1st, 2009) ChemGenex Pharmaceuticals Limited ... its pivotal study of omacetaxine in patients with ... of an oral presentation and discussion today at ... Annual Meeting in Orlando, Florida. The open label ...
... Senators Arlen Specter (D-Pa.) and John Cornyn (R-Tex.) will ... equipment and services during the American Association for Homecare ... Hilton. , , During the week, ... institute fundamental reforms to Medicare policy for durable medical ...
Cached Medicine News:Health News:'Viewers Beware' Report by Watchdog Group Exposes Conservative Group Behind Anti-Healthcare Ads Running in Virginia 2Health News:Many Childhood Cancer Survivors Not Checking for Second Malignancies 2Health News:Many Childhood Cancer Survivors Not Checking for Second Malignancies 3Health News:ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis 2Health News:ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis 3Health News:Minnesota Health Plans Select IGI and ORBIT(R) to Power First State-Mandated Shift to Standardized, Electronic Data Exchange between Plans and Providers 2Health News:Minnesota Health Plans Select IGI and ORBIT(R) to Power First State-Mandated Shift to Standardized, Electronic Data Exchange between Plans and Providers 3Health News:ChemGenex's omacetaxine may provide first viable treatment option for highly resistant form of CML 2Health News:Senators Arlen Specter and John Cornyn Will Discuss Medicare Issues at American Association for Homecare Legislative Conference, June 2-3, 2009 2Health News:Senators Arlen Specter and John Cornyn Will Discuss Medicare Issues at American Association for Homecare Legislative Conference, June 2-3, 2009 3
(Date:1/15/2014)... 2014  Celsion Corporation (the "Company") (NASDAQ: CLSN ... institutional investors to purchase an aggregate of approximately $15 ... registered direct offering, led by a dedicated health care ... agreements with these investors pursuant to which the Company ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... an unprecedented effort to curb the spread of "superbugs" such as ... an advanced and portable UV germicidal lamp manufactured by MRSA-UV is ... In order to prevent EMS paramedics and transport patients ... Palm Beach Fire Rescue is the first in the ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... Small Molecules ... NEW YORK, Aug. 7 Historically, bile acids ... the absorption of,dietary lipids and cholesterol homeostasis. However, ... broader systemic endocrine,functions, acting as important mediators of ...
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) reported today financial ... 30, 2008 and provided an update,on the Company,s progress ... quarter and six month period ended June 30, 2008, ... the United,States (GAAP), was $14.1 million and $28.7 million, ...
Cached Medicine Technology:Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling 2Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling 3Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 2Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 3Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 4Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 5Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 6Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 7Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 8Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 9Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 10Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 11
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: